Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New arthritis drug shows promise in Long-Term safety trial

NCT ID NCT07223138

Disease control Sponsor: MoonLake Immunotherapeutics AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug controls arthritis symptoms over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,560 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who, in the opinion of the investigator, are expected to benefit from participation in this OLE study. 2. Participants who have received the second to last and/or last dose, as planned in the parental study, and have completed the end-of-treatment visit of the parental study. 3. Participants must have received their last dose of study treatment in the parental study no more than 8 weeks (but ideally 4 weeks) before the first dose in this OLE study. 4. Female participants are eligible to participate if they are not pregnant or breastfeeding and must be of nonchildbearing potential or must agree to use highly effective methods of contraception during the study and for at least 8 weeks after the last dose of study treatment. Female participant of childbearing potential must refrain from donating oocytes during the study and for at least 8 weeks after the last dose of study treatment. 5. Male participants must be willing to use a condom when sexually active with a partner of childbearing potential during the study and for at least 8 weeks after the last dose of study treatment, unless surgically sterile. Male participants must also agree to refrain from donating sperm during the study and for at least 8 weeks after the last dose of study treatment. Exclusion Criteria: 1. Participants who met any of the discontinuation criteria of the parental study at the time of enrollment in this OLE study. 2. Participants who have ongoing or planned use of one or more of the prohibited PsA or non-PsA treatments specified in this protocol. 3. Participants who plan to participate in another interventional study for a drug or device during this study. 4. Participants who were unblinded during the parental study. 5. Participant noncompliance to the parental study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis, psoriatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis, psoriatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Site

    Avondale, Arizona, 85392, United States

  • Clinical Site

    Mesa, Arizona, 85210, United States

  • Clinical Site

    Phoenix, Arizona, 85032, United States

  • Clinical Site

    Scottsdale, Arizona, 85260, United States

  • Clinical Site

    Tucson, Arizona, 85748, United States

  • Clinical Site

    Jonesboro, Arkansas, 72401, United States

  • Clinical Site

    Upland, California, 91786, United States

  • Clinical Site

    Avon Park, Florida, 33825, United States

  • Clinical Site

    Clearwater, Florida, 33765, United States

  • Clinical Site

    Tampa, Florida, 33607, United States

  • Clinical Site

    Charlotte, North Carolina, 28262, United States

  • Clinical Site

    Leland, North Carolina, 28451, United States

  • Clinical Site

    Middleburg Heights, Ohio, 44130, United States

  • Clinical Site

    Duncansville, Pennsylvania, 16635, United States

  • Clinical Site

    Memphis, Tennessee, 38119, United States

  • Clinical Site

    Baytown, Texas, 77521, United States

  • Clinical Site

    Lubbock, Texas, 79424, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.